

FREE FOR PUBLICATION 10 FEBRUARY 2006 AT 07:00 GMT

NORA KAARELA APPOINTED AS THE NEW CHIEF EXECUTIVE OFFICER OF IPSAT THERAPIES LTD.

Helsinki, Finland, xx February, 2006. Ipsat Therapies announces the appointment of Nora Kaarela, M.Sc.(Med.Eng.), MBA (IMD) as Chief Executive Officer. Nora Kaarela possesses 20 years of broad professional experience in the international healthcare and biotechnology industry. She most recently served as Vice President Business Development and Head of Pharmacogenetics and Diagnostics at Jurilab Ltd.

Nora Kaarela has worked in several segments of life sciences business, including diagnostics, patient monitoring, cancer treatment support therapies and e-Health. Before returning to Finland in 2002 to join Jurilab, Nora Kaarela worked in London as Director of Business Development at Medical Exchange Online Ltd, heading up the company's European expansion strategy. In Germany and the UK, Nora Kaarela served Baxter Biotech as European Marketing Director. She has lived in six countries and speaks six languages.

Ipsat Therapies has already demonstrated the proof of concept for its first product in healthy volunteers, which targets the prevention of antibiotic resistance, antibiotic-associated diarrhea and hospital associated infections of penicillin – based antibiotics. The company is looking to recruit partners for the further development of its lead product. *"We are excited that Nora has decided to join Ipsat. Her diverse experience in the pharmaceutical industry as well as her business development skills are a strong fit with the needs and future potential of Ipsat,"* comments Wolfgang Pieken, Chairman of the Board of Ipsat Therapies Ltd. Nora Kaarela is equally excited: *"With a major clinical milestone achieved and backed by international healthcare investors we have a solid basis to tackle Ipsat's future challenges".*

-Ends-

FOR MORE INFORMATION, PLEASE CONTACT:

Nora Kaarela
CEO
Ipsat Therapies Oy
Viikinkaari 4, FI-00790 Helsinki, Finland
Tel: +358 400 89 70 20

Wolfgang Pieken
Chairman of the Board
Ipsat Therapies Oy
Viikinkaari 4, FI-00790 Helsinki, Finland
Tel: +49 1728 225 407

nora.kaarela@ipsat-ther.com
<http://www.ipsat-ther.com/>

wpieken@mac.com
<http://www.ipsat-ther.com/>

NOTES TO EDITORS:

Ipsat Therapies

Ipsat Therapies Ltd is a private company focusing on the development of products in the anti-infective field. Ipsat's primary business is the prevention of antibiotic resistance, antibiotic-associated diarrhea and hospital associated infections. The Company became operational in 1999 and has raised €19 million in funding to date. For more information please visit <http://www.ipsat-ther.com/>.

Hospital Acquired Infections

Treatment of hospital acquired infections accounts for an additional US\$ 4 billion in healthcare costs in the US alone, with a 35% mortality rate. Commonly known resistant pathogens resulting in these serious infections include *Clostridium difficile*, vancomycin-resistant *Enterococci* and other gram-negative bacteria, as well as aggressive yeasts such as *Candida glabrata*.